Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

37.11USD
22 Nov 2017
Change (% chg)

$0.62 (+1.70%)
Prev Close
$36.49
Open
$36.57
Day's High
$38.40
Day's Low
$36.32
Volume
57,694
Avg. Vol
45,597
52-wk High
$42.00
52-wk Low
$19.34

Summary

Name Age Since Current Position

Michael Wolff Jensen

42 2013 Chairman of the Board, Senior Vice President, General Counsel

Jan Moeller Mikkelsen

56 2007 President, Chief Executive Officer, Director

Scott Smith

2016 Chief Financial Officer, Senior Vice President

Lotte Soenderbjerg

53 2007 Senior Vice President, Chief Administrative Officer

Harald Rau

45 2007 Senior Vice President, Chief Scientific Officer

Martin Auster

39 2014 Senior Vice President, Chief Business Officer

Flemming Jensen

55 2015 Senior Vice President, Product Supply

Grethe Rasmussen

52 2008 Senior Vice President, Product Development

Kennett Sprogoee

37 2016 Senior Vice President, Product Innovation

Peter Rasmussen

46 2016 Vice President, Finance and Principal Financial and Accounting Officer

Jonathan Leff

58 2016 Chief Medical Officer

Albert Cha

45 2014 Director

James Healy

52 2014 Director

Martin Olin

47 2014 Director

Jonathan Silverstein

50 2014 Director

Rafaele Tordjman

2007 Director

Biographies

Name Description

Michael Wolff Jensen

Mr. Michael Wolff Jensen, L.L.M. has served as Chairman of the Board of Directors at Ascendis Pharma A/S since January 2008 and as Senior Vice President, General Counsel since June 2013. In addition, Mr. Jensen served as Acting Chief Financial Officer from May 2008 to June 2013. From October 2010 to June 2013, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Dong Energy A/S, the Danish State-owned utility company. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President & Chief Financial Officer of Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S, a publicly traded biotechnology company from 2000 to 2003. Mr. Jensen also currently serves as Chairman of the board of directors of two biotechnology companies; one publicly traded, Eurocine Vaccines AB, and one privately held. Mr. Jensen received an L.L.M. degree from the University of Copenhagen.

Jan Moeller Mikkelsen

Mr. Jan Moeller Mikkelsen serves as President, Chief Executive Officer, Director of Ascendis Pharma A/S. He co-founded Ascendis Pharma and has served as our President and Chief Executive Officer and as a member of our board of directors since December 2007. From 2002 to 2006, Mr. Mikkelsen served as President and Chief Executive Officer of LifeCycle Pharma A/S, now known as Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company. From 2000 to 2002, Mr. Mikkelsen served as Co-President and subsequently as President of the Pharmaceutical Division of Maxygen, Inc., a protein pharmaceuticals business. Mr. Mikkelsen co-founded ProFound Pharma A/S, a biopharmaceutical company that was later acquired by Maxygen, Inc., and he served as Co-Chief Executive Officer from 1999 to 2000. Prior to founding ProFound, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, and served as its Vice President of protein discovery from 1991 to 1999. Mr. Mikkelsen currently serves as a member of the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company. Mr. Mikkelsen is Cand. Scient. in Biochemistry from the University of Odense.

Scott Smith

Mr. Scott T. Smith has been Chief Financial Officer and Senior Vice President of Ascendis Pharma A/S since August 8, 2016. He most recently served as Director of the Healthcare Investment Banking Group at Wedbush Securities, from 2012 to 2016, where he led the healthcare team and oversaw a substantial increase in revenue and transaction volume. From 2009 to 2012, Mr. Smith served as a Managing Director at Wedbush. Prior to joining Wedbush, Mr. Smith served as a Director in the Global Healthcare Investment Banking Group at Merrill Lynch where he began his career in 1995. He has also worked in sales, marketing and strategy roles for various companies, including start-ups and a Fortune Global 500 company. Mr. Smith received his MBA from the Stanford University Graduate School of Business and graduated magna cum laude with a BA in Economics/Accounting - Physics from Claremont McKenna College.

Lotte Soenderbjerg

Ms. Lotte Soenderbjerg serves as Senior Vice President, Chief Administrative Officer at Ascendis Pharma A/S since December 2007. She has been Managing Director of Ascendis Pharma GmbH at the Company. Prior to joining Ascendis Pharma, Ms. Soenderbjerg served as Senior Director of Human Resources and as Finance Director at Veloxis Pharmaceuticals A/S from 2003 to 2007. Prior to joining Veloxis Pharmaceuticals A/S, Ms. Soenderbjerg served as Senior Director of Finance and Human Resources at Acadia Pharmaceuticals Inc., a publicly traded biotechnology company from 1996 to 2003. Prior to her career in biotech, Ms. Soenderbjerg was the Executive Secretary for the CEO and Board of Directors of Novo Nordisk A/S. Ms. Soenderbjerg received a Masters of Arts in International Business Communications from University of Aarhus.

Harald Rau

Dr. Harald Rau has served as Senior Vice President, Chief Scientific Officer at Ascendis Pharma A/S since December 2007. He has been managing the research group at Ascendis Pharma since December 2007. Prior to Ascendis Pharma, Dr. Rau served as the Chief Scientific Officer of Complex Biosystems GmbH, a biotechnology company Dr. Rau co-founded in 2002, which was acquired by Ascendis Pharma in December 2007. Prior to co-founding Complex Biosystems, Dr. Rau worked with Graffinity Pharmaceuticals AG, a biotechnology company, from 1998 to 2002, and served as its Director of Chemistry from 2000 to 2002. Dr. Rau obtained his doctorate from the University of Freiburg.

Martin Auster

Dr. Martin D. Auster, M.D. has been Senior Vice President and Chief Business Officer of Ascendis Pharma A/S since May 2014. Prior to Ascendis Pharma, Dr. Auster served as Vice President, Business Development at United Therapeutics Corporation, a publicly traded biotechnology company, from March 2009 to May 2014. Prior to United Therapeutics, Dr. Auster held several positions in the investment banking industry including as a Biotechnology Analyst at Morgan Stanley, as a Senior Biotechnology Analyst at Wachovia Securities, and as a Senior Analyst at GLG Partners, Inc. Dr. Auster received a B.A. from the University of Michigan and an M.D. from the University of Texas Medical Branch.

Flemming Jensen

Mr. Flemming Steen Jensen has served as Senior Vice President, Product Supply of Ascendis Pharma A/S since August 2015. Prior to this, Mr. Jensen served as Corporate Vice President for Global Pharma Consulting and Business Development and member of the management team at NNE Pharmaplan A/S, an engineering and consulting company (part of Novo Nordisk A/S), from October 2014 to July 2015. From 1999 to September 2014, Mr. Jensen served as Executive Vice President of Product Supply (Production, Supply Chain, Engineering and Maintenance, Business Improvements, Quality Assurance and Health, Safety and Environment) and member of the Board of Management of ALK-Abello A/S, a pharmaceutical company. From 1986 to 1999, Mr. Jensen held several management positions relating to Development, Manufacturing and Engineering within Novo Nordisk A/S, a pharmaceutical company. Mr. Jensen is also a member of various boards of directors and advisory boards of privately held companies in the life sciences industry. Mr. Jensen holds a M.Sc. in Pharmacy from the University of Copenhagen.

Grethe Rasmussen

Dr. Grethe Rasmussen, Ph.D. has served as Senior Vice President, Product Development at Ascendis Pharma A/S since April 2008. From 2000 to 2007, Dr. Rasmussen served as Vice President for Protein Science at Maxygen, Inc. and from 2007, she served as Managing Director for the Danish subsidiary of Maxygen. Prior to joining Maxygen from 1989 to 2000, Dr. Rasmussen held various positions at Novo Nordisk A/S, a global healthcare company, where she contributed to research and development of protein chemistry. Dr. Rasmussen received a Ph.D. in Biochemistry from the Danish Technical University.

Kennett Sprogoee

Mr. Kennett Sprogoee, Ph.D. has been Senior Vice President, Product Innovation of Ascendis Pharma A/S since January 2016. He has held positions of increasing responsibility at Ascendis Pharma since December 2007 and as Vice President, Product Innovation from June 2014 to January 2016 and Director, Portfolio Development from November 2012 to June 2014. Prior to joining Ascendis Pharma, Dr. Sprogoee conducted research at the University of Copenhagen, where he applied novel hyphenated screening technologies to expedite discovery of drug leads from natural sources. Dr. Sprogoee holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen and a M.Sc. in Pharmacy from the Danish University of Pharmaceutical Sciences.

Peter Rasmussen

Mr. Peter Rasmussen has been Vice President, Finance and Principal Financial and Accounting Officer of Ascendis Pharma A/S since February 2016. He has been Principal Accounting Officer, Vice President - Finance at the Company since March 2014. Prior to joining Ascendis Pharma, Mr. Rasmussen worked as a financial consultant for Ascendis Pharma from October 2013 to March 2014. From June 2008 to August 2012, Mr. Rasmussen served as the Chief Financial Officer of AdvanDx, Inc., a privately held medical device company. From 2007 to 2008, prior to AdvanDx, Mr. Rasmussen served as Head of Finance at Veloxis Pharmaceuticals A/S. Mr. Rasmussen is a state-authorized public accountant in Denmark and received an M.Sc. in Business Economics and Auditing from Copenhagen Business School.

Jonathan Leff

Dr. Jonathan A. Leff, M.D. is Chief Medical Officer of Ascendis Pharma A/S since February 25, 2016. From March 2015 until joining Ascendis Pharma, Dr. Leff consulted with various clients in the field of clinical development. Prior to joining Ascendis Pharma, Dr. Leff served as the Executive Vice President, Research and Development for InterMune, Inc., a biotechnology company, from February 2012 to March 2015. Prior to InterMune, Dr. Leff served as Chief Medical Officer from February 2011 to February 2012 at KaloBios Pharmaceuticals, Inc., a biotechnology company, and previously served as Vice President and Chief Medical Officer at Halozyme Therapeutics, Inc. from 2009 to 2010. Prior to joining Halozyme from 2007 to 2009, Dr. Leff was Vice President and Global Head of Inflammation Clinical Development at Roche. From 2002 to 2007, Dr. Leff held various positions at Amgen Inc., including Vice President, North American Medical Affairs. Dr. Leff received a B.A. in Chemistry from the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.

Albert Cha

Dr. Albert Cha, M.D., Ph.D. has been Member of the Board of Directors of Ascendis Pharma A/S since November 2014. In 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions, most recently as a managing partner. Dr. Cha currently serves as a member of the board of directors of several privately held biotechnology and medical device companies. Dr. Cha serves as a member of the board of directors at the following publicly traded companies: AirXpanders Inc., Aclaris Therapeutics, Inc., Carbylan Therapeutics, Inc., and ProNAi Therapeutics, Inc. From June 2002 through February 2009, Dr. Cha served as a member of the board of directors at BioForm Medical, Inc., a publicly traded medical aesthetics company. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.

James Healy

Dr. James I. Healy, M.D., Ph.D. has served as a Member of the Board of Directors of Ascendis Pharma A/S since November 2014. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Amarin Corporation plc, Auris Medical Holding AG, Hyperion Therapeutics, Inc., Coherus BioSciences, Inc. and several private companies. Previously, he served as a board member of InterMune, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV, KaloBios Pharmaceuticals, Inc. and several private companies. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

Martin Olin

Mr. Martin Olin has served as a Member of the Board of Directors of Ascendis Pharma A/S since June 2014. Since March 2012, Mr. Olin has served as the Chief Financial Officer of Symphogen A/S, a privately held biotechnology company, and, since February 2016, Mr. Olin has also served as Symphogen’s Deputy Chief Executive Officer. Prior to his positions with Symphogen, Mr. Olin served as an Investment Director of SLS Invest ApS, a venture capital firm specializing in life sciences companies from January 2009 to March 2012. Prior to SLS Invest, Mr. Olin served as a Senior Partner of Scandinavian Life Science Venture, a life-science focused venture capital company later acquired by SLS Invest. Mr. Olin holds a B.Sc. in Business and Administration from Vestsjaellands Business School, an M.Sc. in Auditing and Business Administration from Copenhagen Business School and an Executive M.B.A. from Scandinavian International Management Institute.

Jonathan Silverstein

Mr. Jonathan T. Silverstein, J.D. has served as a Member of the Board of Directors of Ascendis Pharma A/S since November 2014. Mr. Silverstein has been a member of OrbiMed Advisors LLC, an asset management firm solely focused in healthcare, since 1999. Prior to OrbiMed, Mr. Silverstein was a director of life sciences in the investment banking department at Sumitomo Bank, a financial services company. Since August 2012, Mr. Silverstein has served as a director of Intercept Pharmaceuticals, Inc., a biopharmaceutical company; since September 2009, Mr. Silverstein has served as a director of Roka BioScience, Inc., a molecular diagnostics company; and, since July 2008, Mr. Silverstein has served as a director of Glaukos Corporation, an ophthalmic medical device company. In addition, Mr. Silverstein currently serves as a member of the board of directors of a number of private companies. From 2010 to July 2014, Mr. Silverstein was a director of Relypsa, Inc. From 2008 until 2011, Mr. Silverstein was a director of NxStage Medical, Inc. From 2006 until 2008, Mr. Silverstein was a director of Insulet, Inc. From 2004 until 2007, Mr. Silverstein was a director of Avanir Pharmaceuticals, Inc. Mr. Silverstein has a B.A. in economics from Denison University and a J.D. and M.B.A. from the University of San Diego.

Rafaele Tordjman

Dr. Rafaele Tordjman, M.D., Ph.D. has served as a Member of the Board of Directors of Ascendis Pharma A/S since December 2007. Dr. Tordjman joined the French venture capital firm Sofinnova Partners in 2001 and is a Managing Partner specializing in life sciences investments. Dr. Tordjman has also served on the boards of directors at several life sciences companies including DBV Technologies SA, a French publicly traded company specializing in allergy therapies, and Flexion Therapeutics, Inc., a publicly traded company specializing in clinical-stage pharmaceuticals. Previously, Dr. Tordjman was a research scientist at the Institut National de la Sante et de la Recherche Medicale (INSERM) in Cochin Hospital, Paris, France. Dr. Tordjman has also practiced as a medical doctor, specializing in clinical hematology and internal medicine. Dr. Tordjman received an M.D. and completed a fellowship in hematology and internal medicine at the Paris University Hospitals. She received a Ph.D. in hematopoiesis and angiogenesis from and completed a post-doctoral fellowship in immunology, at the University of Paris VII.